Wakefit Innovations has scheduled an earnings conference call for August 7, 2026, at 10:30 AM IST to discuss its unaudited financial results for the first quarter (Q1) of fiscal year 2027 (FY27). This investor engagement follows a board meeting held on August 6 to review the company's performance for the quarter ended June 30, 2026.

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company emphasized that discussions during the call will be based solely on publicly available information, and no Unpublished Price Sensitive Information (UPSI) will be shared. The schedule remains subject to change due to exigencies on the part of investors, analysts, or the company.

Conference Call Details

The earnings call is organized by Capital 360 ONE CM Research. The management team representing Wakefit Innovations Limited will include:

Participants can join the conference via the Diamond Pass link provided by the company or through universal dial-in numbers. International toll-free numbers are available for participants in countries including the USA, UK, Australia, and several European nations. For further assistance, Mr. Akhil Parekh from 360 ONE Capital Market Research has been listed as the contact point.

Regulatory Compliance

The intimation was signed by Surbhi Sharma, Company Secretary and Compliance Officer of Wakefit Innovations Limited (formerly known as Wakefit Innovations Private Limited), on August 3, 2026. The relevant documents and further information have been made available on the company’s website under the investor relations section. Stakeholders are advised to monitor official channels for any updates regarding the timing or format of the proceedings.

Wakefit Innovations has granted 4,57,611 Employee Stock Options (ESOPs) to eligible employees under its Wakefit Employee Stock Option Plan - 2019. The grant, approved by the Nomination and Remuneration Committee (NRC) on July 13, 2026, aims to incentivize employees through equity ownership in the company. The options are priced at Re. 1 per share and will convert into equity shares of the same face value upon exercise.

The allocation of these options is in compliance with the Securities and Exchange Board of India (SEBI) (Share Based Employee Benefits & Sweat Equity) Regulations, 2021. The company confirmed that the scheme adheres to the regulatory framework, ensuring that the grant process meets all necessary disclosure and compliance standards mandated by the market regulator.

Vesting and Exercise Details

The granted options come with specific vesting and exercise timelines designed to align employee interests with long-term company performance. According to the disclosure, the options will vest after a minimum period of 12 months from the Grant Date and not later than 5 years. The actual vesting will be determined based on time and/or performance criteria as outlined in the Letter of Grant, subject to the employee's continued employment.

Once vested, the options can be exercised by the employees. All vested options must be exercised within a maximum period of 1 year from the date of vesting. The company noted that vesting timelines may be extended for unauthorized or non-statutory leaves as per the provisions of the ESOP Plan.

Key Terms of the Grant

The detailed terms of the ESOP grant were disclosed in an annexure to the regulatory filing. The table below summarizes the significant particulars of the options granted:

The company stated that no options have been exercised, lapsed, or varied as of this disclosure, as the announcement pertains strictly to the initial grant. The information regarding the grant has been made available on the company's official investor relations website for shareholder reference.